Boston Scientific Corporation $BSX Shares Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management B.V. trimmed its Boston Scientific stake by 4.0% in Q4, selling 125,991 shares and retaining 2,992,877 shares worth about $285.37 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 at an average price of $93.49 for roughly $15.04 million, a 10.23% reduction in his direct holding.
• Q4 results and guidance: Boston Scientific reported $0.80 EPS (vs. $0.78 estimate) and $5.29B revenue (+15.9% YoY), and set Q1 2026 EPS guidance of $0.780–0.800 and FY2026 EPS guidance of $3.430–3.490; analysts' consensus is a "Moderate Buy" with an average target of $104.05.

Robeco Institutional Asset Management B.V. decreased its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,992,877 shares of the medical equipment provider's stock after selling 125,991 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.20% of Boston Scientific worth $285,371,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Steph & Co. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the third quarter valued at about $25,000. Finally, United Community Bank grew its position in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 147 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX opened at $61.72 on Friday. The firm has a market capitalization of $91.72 billion, a PE ratio of 31.81, a PEG ratio of 0.95 and a beta of 0.78. Boston Scientific Corporation has a twelve month low of $60.59 and a twelve month high of $109.50. The firm's 50-day moving average price is $71.47 and its 200 day moving average price is $88.07. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific's quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA cleared Boston Scientific’s Asurys Fluid Management System (510(k)), a perioperative fluid-management product that expands the company’s procedural portfolio and supports recurring consumables revenue and long-term growth narrative. This type of clearance can help justify premium growth multiples if adoption follows. Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System
• Neutral Sentiment: Street forecasts and FY2026 earnings expectations are being updated across outlets; investors should watch consensus revisions which can drive near-term volatility even if underlying fundamentals stay intact. Equities Analysts Offer Predictions for BSX FY2026 Earnings
• Neutral Sentiment: Sector moves and startup funding (e.g., E2’s $80M raise for thrombectomy tech) highlight ongoing competition and innovation in device segments where Boston Scientific competes; these developments are worth monitoring for market-share and M&A implications. E2 raises $80M to market thrombectomy platform
• Negative Sentiment: Multiple law firms have issued shareholder alerts and a securities class action has been filed, with a May 4, 2026 deadline for lead plaintiff motions. Consolidation of claims or a lead plaintiff could increase litigation costs, create disclosure risk, and pressure sentiment while the case proceeds. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: At least one major broker (Citigroup) has lowered expectations for BSX, which can prompt further analyst downgrades and price pressure if others follow. Monitor analyst notes for revised revenue/margin forecasts. Citigroup Has Lowered Expectations for Boston Scientific NYSE: BSX Stock Price

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. UBS Group dropped their target price on shares of Boston Scientific from $120.00 to $105.00 and set a "buy" rating on the stock in a research report on Tuesday, March 17th. Argus upgraded shares of Boston Scientific to a "strong-buy" rating in a research report on Thursday, February 26th. Jefferies Financial Group restated a "buy" rating on shares of Boston Scientific in a research report on Monday, March 16th. Robert W. Baird lowered their price target on shares of Boston Scientific from $118.00 to $101.00 and set an "outperform" rating on the stock in a research report on Thursday, February 5th. Finally, Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $104.05.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.